Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).


TSXV:MPH - Post by User

Bullboard Posts
Post by dotbombnoton Aug 28, 2001 7:56pm
983 Views
Post# 4143959

more news!!PR Firm!!Aug /29/01

more news!!PR Firm!!Aug /29/01Medicure hires PR firm Medicure Inc MPH Shares issued 20,128,685 2001-08-27 close $1 Tuesday Aug 28 2001 News Release Mr. Dawson Reimer reports Medicure has retained the Equicom Group Inc. to provide Medicure with investor relations services. Dr. Albert Friesen, president and chief executive officer, Medicure, stated: "Investor communication is a key part of being a public company and we expect that the agreement with Equicom will be an important, strategic step in increasing our company's exposure to investors and key individuals across Canada. As a young CDNX company we see tremendous opportunity as we bring our story to a broader and larger audience." From its Toronto headquarters, the Equicom Group Inc. provides financial communication services to Canadian companies and has proven expertise in the life sciences field. Equicom will handle all investor relations services on behalf of Medicure, including investor communications, marketing materials and Web site development; in addition, Equicom will offer strategic and consulting services to the company with respect to matters such as future financings, acquisitions and exchange listings. Under the terms of the 12-month agreement, Equicom will receive $7,000 per month and a total of 30,000 share purchase options. The principals of the Equicom Group are Barry Hildred, president, and Jason Hogan, executive vice-president. (c) Copyright 2001 Canjex Publishing Ltd. https://www.canada-stockwatch.com old url (better for printing)
Bullboard Posts